Auroch Biosciences is a San Diego–based preclinical stage company that recently emerged from stealth founded and advised by scientists from the Scripps Research Institute developing next generation biologics.

Auroch’s platform leverages antibody fragments known as “knobs” to rapidly generate novel constructs with potential applications in oral/ GI biologics. These knobs represent the smallest functional antibody fragments ever described—approximately the size of an insulin molecule—and have broad utility as bi- or tri-specifics, multivalents, and more. The founders have been optimizing this scaffold for over 15 years, derisking the platform to the point where lead molecules are now ready to advance.

Our objective for this conference is to meet with potential investors and Pharma/Biotech companies.

Due to a packed schedule, we will not be taking meetings from Service Providers